当前位置: X-MOL 学术Nat. Rev. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serelaxin treatment does not reduce incidence of death in patients with AHF.
Nature Reviews Cardiology ( IF 41.7 ) Pub Date : 2019-11-01 , DOI: 10.1038/s41569-019-0264-4
Karina Huynh 1
Affiliation  

In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure.

中文翻译:

Serelaxin 治疗不会降低 AHF 患者的死亡率。

在急性心力衰竭患者中,使用人松弛素 2 的重组形式 serelaxin 治疗并没有降低心血管死亡或心力衰竭恶化的发生率。
更新日期:2019-09-03
down
wechat
bug